Vitamin K Dosing for INR 7.49
For a patient with an INR of 7.49 who is not bleeding and has no high-risk bleeding factors, administer oral vitamin K 1 to 2.5 mg and hold warfarin. If the patient has increased bleeding risk factors (age ≥65, history of stroke, GI bleeding, renal insufficiency, or concurrent antiplatelet therapy), this approach is particularly important 1.
Clinical Context and Risk Assessment
An INR of 7.49 falls within the 5-9 range, which carries significantly increased bleeding risk but still relatively low absolute daily bleeding risk (<5.5 per 1000 per day) 2. The key decision point is whether the patient is actively bleeding or has high-risk features for bleeding.
For Non-Bleeding Patients (Most Common Scenario)
Management approach:
- Omit the next 1-2 doses of warfarin
- Administer oral vitamin K 1 to 2.5 mg 1
- Monitor INR closely and repeat as necessary
The evidence strongly supports oral administration over other routes. Oral vitamin K is predictably effective, safer than IV administration (which carries anaphylaxis risk), and more reliable than subcutaneous administration (which has unpredictable and delayed response) 1.
Expected response: The INR should decrease to <5 within 24 hours. In a prospective study of 62 patients with INR 4-10 who received 1 mg oral vitamin K, 95% had INR reduction within 24 hours, with 85% achieving INR <4 and 35% reaching INR <1.9, without causing warfarin resistance 1, 3.
If More Rapid Reversal Needed
If urgent surgery or dental extraction is required within 24 hours, increase the oral vitamin K dose to 2 to 5 mg, anticipating INR reduction within 24 hours 1. An additional 1-2 mg can be given if INR remains elevated after 24 hours 1.
Route of Administration Considerations
Oral route is strongly preferred for the following reasons:
- Safety: No anaphylaxis risk (unlike IV) 1
- Predictability: More reliable than subcutaneous administration 1
- Convenience: Easier to administer
- Efficacy: Oral vitamin K 1-2.5 mg effectively reduces INR to therapeutic range within 24 hours 3
IV administration should be reserved only for:
- Active serious bleeding
- Emergency surgery that cannot wait 24 hours
- Patient unable to take oral medications
If IV is necessary, use slow infusion over 30 minutes at 5-10 mg to minimize anaphylaxis risk 1.
Dosing Nuances
The guideline evidence clearly states that oral vitamin K 1.0 to 2.5 mg is sufficient when INR is between 4 and 10 1. Larger doses (5 mg) are reserved for INR ≥10 1.
Critical pitfall to avoid: High doses of vitamin K (e.g., 10 mg) may lower INR more than necessary and cause warfarin resistance for up to a week 1. This creates difficulty when restarting anticoagulation and may expose the patient to thrombotic risk.
Monitoring and Follow-up
- Recheck INR at 24 hours after vitamin K administration
- If INR remains >5, consider repeating vitamin K 1-2 mg
- Once INR approaches therapeutic range, restart warfarin at a reduced dose (not the original dose)
- Continue close INR monitoring during warfarin resumption
Special Considerations for Mechanical Valve Patients
In patients with mechanical heart valves (particularly mitral valves), the balance between bleeding and thrombotic risk is more precarious. The 2014 AHA/ACC guidelines recommend low-dose vitamin K (1-2 mg oral) for elevated INR to avoid creating a hypercoagulable state 4. High-dose vitamin K should not be given routinely as it may create excessive reversal and increase thrombotic risk 4.
Evidence Quality Note
While newer research has explored tailored dosing based on INR and body surface area 5, the established guideline recommendations from the American College of Chest Physicians and AHA/ACC remain the standard of care 1, 4. The FDA labeling supports doses of 2.5-10 mg for anticoagulant-induced prothrombin deficiency 6, but clinical guidelines favor the lower end of this range for INR 5-9 to avoid overcorrection.